stroke.

Tavi en pacientes com bajo flujo, bajo gradiente clásico

TRICENTO: Promising Results for Severe Tricuspid Valve Regurgitation

Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table.   Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices.  The TRICENTO has an...

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

REVERSE-IT | Bentracimab: Progress on the Antidote for Ticagrelor in Emergency Scenarios

Optimizing an antiplatelet therapy after an acute coronary syndrome (ACS) aims at reducing the major adverse cardiac events (MACE) caused by atherosclerotic disease. Ticagrelor is a potent P2Y12 inhibitor that directly prevents platelet activation. It is characterized by a rapid and consistent onset of action throughout its administration (twice daily) and its proven pleiotropic effects,...

enfermedad carotídea y coronaria severa

Symptomatic Carotid Arteries: Early or Late Emergency Revascularization?

Carotid endarterectomy continues to be the safest technique for emergency revascularization. However, 48 hours after index event, different strategy outcomes will become comparable.  Multiple advances in device development have brought promising results for carotid revascularization patients with symptomatic stenosis. Regardless these developments, optimal revascularization timing after index event remains unclear.  This study included patients with...

The Most Read Articles of 2021 - Peripheral Vascular Disease

The Most Read Articles of 2021: Peripheral Vascular Disease

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, peripheral vascular disease. Follow us to keep up to date. 01- SOLACI PERIPHERAL | 6th Clinical Case: Common, Superficial and Deep Femoral Artery Recanalization Dr. Ana Paula Mollón (Arg.)...

Fibrilación auricular y demencia ¿Qué anticoagulante tiene el menor riesgo?

Atrial Fibrillation and Dementia: Which Anticoagulant Agent Presents the Lowest Risk?

Atrial fibrillation is a risk factor for dementia and anticoagulant agents have been proven to decrease it. This work aims to find differences in the risk of dementia between patients treated with traditional choice warfarin vs. different direct anticoagulants. Between 2014 and 2017, this study enrolled 72,846 patients >40 years with nonvalvular atrial fibrillation who...

Can Ticagrelor Prevent Strokes in High-Risk Patients?

In addition to aspirin, Ticagrelor offers better prognosis in patients that already had a stroke and have a high-risk cardiovascular profile. These benefits should be correctly balanced seeing as they are not free of risk.  Antiplatelet therapy makes part of the standard treatment of cardiac or cerebrovascular patients. Ticagrelor has shown superior to clopidogrel in...

ESC 2021 | COVERT-MI: Colchicine Attempts to Reduce Infarct Size

Colchicine does not offer protection against myocardial injury in ST-segment elevation myocardial infarction when administered during reperfusion and in the following five days, according to the randomized study COVERT-MI. It could even generate signs of damage with 3x the amount of thrombi in the ventricle. The results presented at the European Society of Cardiology 2021...

¿Desescalar la doble antiagregación es el nuevo paradigma?

Dual Antiaggregation De-Escalation: A New Paradigm?

De-escalating dual antiaggregation could be the most effective strategy after acute coronary syndrome seeing as it prevents bleeding and cut down costs with no increase of ischemic events.  Balancing the effects of dual antiaggregation therapy (DAPT) in the era of potent P2Y12 inhibitors has become the cornerstone of acute coronary syndrome (ACS) management.  This meta-analysis...

TAVI SURAVI

European Consensus on Antithrombotic Management in TAVR

All the controlled randomized evidence recently published called for an updated document on antithrombotic management in transcatheter aortic valve replacement (TAVR). While thrombotic and hemorrhagic complications have diminished over time—as both the technique and the devices have been perfected—, they still remain as common adverse events in TAVR.  Recommendations in the 2017 European Guidelines were...

Top